ENANTA PHARMACEUTICALS INC — Investor Relations & Filings
Filings indexed
812
across all filing types
Latest filing
2024-11-14
Major Shareholding Noti…
Country
US
United States of America
Listing
US
ENTA
Enanta Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops small molecule drugs, with a focus on virology and immunology. The company utilizes a robust, chemistry-driven approach to create novel oral therapeutics for diseases with high unmet medical needs. Enanta has a significant track record of success, having developed protease inhibitors that are key components of treatment regimens for chronic hepatitis C virus (HCV) infection, which have cured over one million patients. Its current clinical pipeline is primarily focused on developing treatments for respiratory syncytial virus (RSV) and advancing its immunology programs for inflammatory diseases.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Major Shareholding Notification 2024 | 2024-11-14 | English | |
| Major Shareholding Notification 2024 | 2024-10-17 | English | |
| STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 2024-08-09 | English | |
| 10-Q | 2024-08-07 | English | |
| 8-K | 2024-08-05 | English | |
| STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 2024-07-15 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2024
15 filings
| |||||
| 11540529 | Major Shareholding Notification 2024 | 2024-11-14 | English | ||
| 11540531 | Major Shareholding Notification 2024 | 2024-10-17 | English | ||
| 11540530 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 2024-08-09 | English | ||
| 11540533 | 10-Q | 2024-08-07 | English | ||
| 11540534 | 8-K | 2024-08-05 | English | ||
| 11540535 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 2024-07-15 | English | ||
| 11540536 | Regulatory Filings 2024 | 2024-07-11 | English | ||
| 11540537 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 2024-06-17 | English | ||
| 11540538 | Regulatory Filings 2024 | 2024-06-17 | English | ||
| 11540539 | S-8 | 2024-05-08 | English | ||
| 11540540 | 10-Q | 2024-05-08 | English | ||
| 11540541 | 8-K | 2024-05-06 | English | ||
| 11540542 | STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES | 2024-05-01 | English | ||
| 11540543 | INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES | 2024-05-01 | English | ||
| 11540545 | 8-K | 2024-03-12 | English | ||
Market data
Market data not available
Last price
Market cap
volume
Day range
today
52-week range
trailing
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
ENANTA PHARMACEUTICALS INC via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/33238/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=33238 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=33238 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
Full reference: API reference · OpenAPI schema
cURL
$ curl https://api.financialreports.eu/api/filings/?company=33238 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 33238}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for ENANTA PHARMACEUTICALS INC (id: 33238)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.
We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.